GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (STU:YP2) » Definitions » Shiller PE Ratio

BioLine Rx (STU:YP2) Shiller PE Ratio : (As of Mar. 03, 2025)


View and export this data going back to 2014. Start your Free Trial

What is BioLine Rx Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioLine Rx Shiller PE Ratio Historical Data

The historical data trend for BioLine Rx's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Shiller PE Ratio Chart

BioLine Rx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioLine Rx Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioLine Rx's Shiller PE Ratio

For the Biotechnology subindustry, BioLine Rx's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLine Rx's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Shiller PE Ratio falls into.



BioLine Rx Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

BioLine Rx's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, BioLine Rx's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-2.624/133.0289*133.0289
=-2.624

Current CPI (Sep. 2024) = 133.0289.

BioLine Rx Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 -58.392 99.070 -78.408
201503 -55.994 99.621 -74.772
201506 -48.114 100.684 -63.571
201509 -16.038 100.392 -21.252
201512 -38.556 99.792 -51.397
201603 -32.328 100.470 -42.804
201606 -37.380 101.688 -48.901
201609 -42.768 101.861 -55.854
201612 -39.816 101.863 -51.998
201703 -44.880 102.862 -58.042
201706 -26.700 103.349 -34.368
201709 -35.238 104.136 -45.015
201712 -35.490 104.011 -45.391
201803 -29.196 105.290 -36.888
201806 -25.680 106.317 -32.132
201809 -30.852 106.507 -38.535
201812 -26.370 105.998 -33.095
201903 -26.550 107.251 -32.931
201906 -21.240 108.070 -26.146
201909 -16.344 108.329 -20.070
201912 -32.400 108.420 -39.754
202003 -21.720 108.902 -26.532
202006 -15.984 108.767 -19.549
202009 -10.188 109.815 -12.342
202012 -19.728 109.897 -23.881
202103 -10.080 111.754 -11.999
202106 -4.980 114.631 -5.779
202109 -5.100 115.734 -5.862
202112 0.000 117.630 0.000
202203 -5.448 121.301 -5.975
202206 -5.676 125.017 -6.040
202209 -6.060 125.227 -6.438
202212 0.000 125.222 0.000
202303 -5.604 127.348 -5.854
202306 -11.076 128.729 -11.446
202309 -11.244 129.860 -11.518
202312 -5.502 129.419 -5.655
202403 -0.354 131.776 -0.357
202406 0.225 132.554 0.226
202409 -2.624 133.029 -2.624

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioLine Rx  (STU:YP2) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


BioLine Rx Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLine Rx Business Description

Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLine Rx Headlines

No Headlines